Assembly Biosciences
D

ASMB

20.330
USD
0.13
(0.62%)
Market Open
Last updated: · Delayed 15 min
Volume
6,550
EPS
2
Div Yield
-
P/E
16
Market Cap
413,930,917
Related Instruments

Title: Assembly Biosciences

Sector: Healthcare
Industry: Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points.The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Common questions about Assembly Biosciences stock